Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy

Breast Cancer Clinical Trial

— CAPABLE-IT  

Official title:

Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06161233
• Other study ID #: CAPABLE-IT
• Status: Completed
• Phase: N/A
• Start date: May 16, 2023
• Est. completion date: January 31, 2024

Study information

• Verified date: March 2024
• Source: Istituti Clinici Scientifici Maugeri SpA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the CAPABLE study is to compare health-related quality of life in renal cell carcinoma patients who use or do not use a mobile-based application to monitor adverse events for cancer treatment at home. As secondary objectives, the study investigates the usability of the system and its generalizability to other cancer types

Description:

The study is designed as a prospectively enrolling, quasi-experimental cohort study in cancer patients, eligible for systemic treatment. The CAPABLE cohort will receive the smartphone application and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months after enrollment. If, after 6 months, a patient wants to keep using the system, he will be allowed to do so, until the end of the study. Questionnaires on health-related quality of life will be administered to the patients on baseline (T0) and every three months (T1 and T2). Lost to follow-up data will be included in intention-to-treat analysis. Qualitative and quantitative user experience studies will be done at enrollment, after 3 months and at the end of the follow-up period with the CAPABLE system. Results of this interventional study will be compared with a control cohort consisting of renal cell carcinoma patients, recruited in 2021 with the same inclusion criteria as this study population, but receiving standard care (ICSM CE number 2546, dated 13/04/2021 and amended on 09/02/2022).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: January 31, 2024
• Est. primary completion date: January 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults (age >=18 years)
• Sufficient understanding of the Italian language
• Patients or their caregiver (upon patient's consent) can use a smartphone
• Histologically or cytologically confirmed diagnosis of RCC, lung, breast, thyroid o head and neck cancer
• Candidate to systemic treatment (targeted agents, immune checkpoint inhibitors, or a combination of the two)
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at the start of the treatment.

Exclusion Criteria:

• Recruitment and consent denial
• Not able of understanding and complying with the protocol requirements (including basic technological abilities)
• Given the fact that each subject involved in the clinical study must be able to understand and sign the informed consent presented by the researcher, lack of this capability represents a specific exclusion criterion in the study protocol.

Related Conditions & MeSH terms

• Breast Cancer
• Carcinoma, Renal Cell
• Head and Neck Cancer
• Lung Cancer
• Ovarian Neoplasms
• Ovary Cancer
• Renal Cell Carcinoma Metastatic
• Stomach Cancer
• Stomach Neoplasms
• Thyroid Cancer

Intervention

Device:
• CAPABLE cohort
The CAPABLE cohort receives the mobileapplication and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months. The CAPABLE app serves three main functionalities for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing

Locations

Country	Name	City	State
Italy	Istituti Clinici Scientifici Maugeri Spa SB	Pavia

Sponsors (13)

Lead Sponsor	Collaborator
Istituti Clinici Scientifici Maugeri SpA	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Associazione Italiana Malati di Cancro AIMAC, Biomeris srl, Bitsens JSC, Deontics LTD, IBM Research, Policlinico di Bari Ospedale Giovanni Paolo XXIII, Poznan University of Technology, The Netherlands Cancer Institute NKI, Universidad Politecnica de Madrid, University of Haifa, University of Pavia

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in health-related QoL outcomes in RCC patients	The primary objective of this study is to investigate whether HRQoL of RCC patients eligible for systemic treatment can be improved by a patient-centred mobile coaching- and monitoring system	6 months after the enrollment
Secondary	User experience of the CAPABLE system in RCC patients	This study will gather qualitative and quantitative information to quantify usefulness, easiness, acceptability and feasibility of the end users' solutions. The patient app will be assessed also in terms of perceived impact and support derived from the digital technologies. The health professional web application will be evaluated to understand to what extent this can be integrated and adopted in the clinical practice	6 months after the enrollment
Secondary	User experience of the CAPABLE system in other cancer types patients	To evaluate the generalizability of the system on other cancer types, the user experience study is performed also on patients with cancer types different from RCC (e.g Breast, Ovary, Head&Neck cancer). The patient app will be assessed also in terms of perceived impact and support derived from the digital technologies. The health professional web application will be evaluated to understand to what extent this can be integrated and adopted in the clinical practice	6 months after the enrollment